Alkermes (ALKS) has issued an announcement.
Alkermes plc has announced encouraging preliminary results from a phase 1b study of their new oral drug, ALKS 2680, aimed at treating narcolepsy type 2 and idiopathic hypersomnia. This milestone could be of great interest to investors tracking advancements in the biopharmaceutical sector, as the company progresses with a treatment that addresses sleep disorders with a novel mechanism of action.
For detailed information about ALKS stock, go to TipRanks’ Stock Analysis page.
